Literature DB >> 26291546

Screening Community Pharmacy Patients for Risk of Prescription Opioid Misuse.

Gerald Cochran1, Jessica Rubinstein, Jennifer L Bacci, Thomas Ylioja, Ralph Tarter.   

Abstract

OBJECTIVES: This study tested screening feasibility and described the behavioral, mental, and physical health of patients filling prescriptions for opioid medications in the community pharmacy setting.
METHODS: We conducted a cross-sectional survey in rural/urban community pharmacies with adult noncancer patients. The survey included validated measures for opioid medication misuse risk, drug and alcohol use, and physical and mental health problems. Descriptive statistics were calculated, and bivariate and multivariable logistic regression evaluated relationships between opioid medication misuse risk and patient demographics, behavioral, mental, and physical health.
RESULTS: A total of 164 patients completed the survey (87% response rate), revealing positive screens for prescription opioid misuse risk (14.3%), illicit drug use (7.3%), hazardous alcohol use (21.4%), depression (25.8%), and posttraumatic stress disorder (PTSD; 17.1%). Bivariate analyses revealed increased odds of a positive opioid medication misuse risk score with a positive screen for illicit drug use in the previous year (odds ratio = 3.91; 95% confidence interval [CI], 1.05-14.63) and PTSD (odds ratio = 6.7; 95% CI, 2.54-17.69). In adjusted multivariable analyses, these relationships strengthened such that a positive screen for illicit drug use (adjusted odds ratio = 12.96; 95% CI, 2.18-76.9) and PTSD (adjusted odds ratio = 13.3; 95% CI, 3.48-50.66) increased odds for a positive opioid medication misuse risk score.
CONCLUSIONS: Findings confirmed the feasibility of screening risk factors and positive opioid medication misuse risk among community pharmacy patients. Future research should validate these findings as a foundation to intervention development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26291546      PMCID: PMC4725054          DOI: 10.1097/ADM.0000000000000148

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  31 in total

1.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 2.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

3.  Construct validity of the SF-12 in three different samples.

Authors:  Ulf Jakobsson; Albert Westergren; Susanne Lindskov; Peter Hagell
Journal:  J Eval Clin Pract       Date:  2011-01-06       Impact factor: 2.431

4.  Mechanisms of prescription drug diversion among drug-involved club- and street-based populations.

Authors:  James A Inciardi; Hilary L Surratt; Steven P Kurtz; Theodore J Cicero
Journal:  Pain Med       Date:  2007-03       Impact factor: 3.750

5.  Prescription drug monitoring programs and death rates from drug overdose.

Authors:  Leonard J Paulozzi; Edwin M Kilbourne; Hema A Desai
Journal:  Pain Med       Date:  2011-02-18       Impact factor: 3.750

6.  Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity.

Authors:  Andrea Meier; Chantal Lambert-Harris; Mark P McGovern; Haiyi Xie; Melissa An; Bethany McLeman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-05-08       Impact factor: 3.829

7.  Prevalence and cost of diagnosed opioid abuse in a privately insured population in the United States.

Authors:  Carl L Roland; Ashish V Joshi; Jack Mardekian; Steven C Walden; James Harnett
Journal:  J Opioid Manag       Date:  2013 May-Jun

8.  Epidemiology of regular prescribed opioid use: results from a national, population-based survey.

Authors:  Teresa J Hudson; Mark J Edlund; Diane E Steffick; Shanti P Tripathi; Mark D Sullivan
Journal:  J Pain Symptom Manage       Date:  2008-07-10       Impact factor: 3.612

9.  Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.

Authors:  Janet S Knisely; Martha J Wunsch; Karen L Cropsey; Eleanor D Campbell
Journal:  J Subst Abuse Treat       Date:  2008-07-26

10.  Potential misuse and inappropriate prescription practices involving opioid analgesics.

Authors:  Ying Liu; Joseph E Logan; Leonard J Paulozzi; Kun Zhang; Christopher M Jones
Journal:  Am J Manag Care       Date:  2013-08       Impact factor: 2.229

View more
  12 in total

1.  Prescription opioid use: Patient characteristics and misuse in community pharmacy.

Authors:  Gerald Cochran; Jennifer L Bacci; Thomas Ylioja; Valerie Hruschak; Sharon Miller; Amy L Seybert; Ralph Tarter
Journal:  J Am Pharm Assoc (2003)       Date:  2016-03-24

2.  Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.

Authors:  Aaron Salwan; Nicholas E Hagemeier; Fred Tudiver; KariLynn Dowling-McClay; Kelly N Foster; Jessie Arnold; Arsham Alamian; Robert P Pack
Journal:  J Am Pharm Assoc (2003)       Date:  2020-07-12

3.  Prescription Opioid Misuse Among Rural Community Pharmacy Patients: Pilot Study for Screening and Implications for Future Practice and Research.

Authors:  Gerald T Cochran; Rafael J Engel; Valerie J Hruschak; Ralph E Tarter
Journal:  J Pharm Pract       Date:  2016-07-08

4.  Prescription opioid poisoning across urban and rural areas: identifying vulnerable groups and geographic areas.

Authors:  Magdalena Cerdá; Andrew Gaidus; Katherine M Keyes; William Ponicki; Silvia Martins; Sandro Galea; Paul Gruenewald
Journal:  Addiction       Date:  2016-09-02       Impact factor: 6.526

5.  Behavioral, mental, and physical health characteristics and opioid medication misuse among community pharmacy patients: A latent class analysis.

Authors:  Gerald Cochran; Valerie Hruschak; Jennifer L Bacci; Kenneth C Hohmeier; Ralph Tarter
Journal:  Res Social Adm Pharm       Date:  2016-11-15

6.  Screening for Psychotherapeutic Medication Misuse in Primary Care Patients: Comparing Two Instruments.

Authors:  Sebastian T Tong; Kathryn M Polak; Michael F Weaver; Gabriela C Villalobos; Wally R Smith; Dace S Svikis
Journal:  J Am Board Fam Med       Date:  2019 Mar-Apr       Impact factor: 2.657

7.  The opioid and related drug epidemics in rural Appalachia: A systematic review of populations affected, risk factors, and infectious diseases.

Authors:  Christine A Schalkoff; Kathryn E Lancaster; Bradley N Gaynes; Vivian Wang; Brian W Pence; William C Miller; Vivian F Go
Journal:  Subst Abus       Date:  2019-08-12       Impact factor: 3.716

8.  A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial.

Authors:  Gerald Cochran; Qi Chen; Craig Field; Amy L Seybert; Valerie Hruschak; Amanda Jaber; Adam J Gordon; Ralph Tarter
Journal:  Drug Alcohol Depend       Date:  2019-10-22       Impact factor: 4.492

9.  Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.

Authors:  Gerald Cochran; Julie Bruneau; Nicholas Cox; Adam J Gordon
Journal:  Subst Abus       Date:  2020       Impact factor: 3.716

10.  Brief intervention medication therapy management: Establishment of an opioid misuse intervention model delivered in a community pharmacy.

Authors:  Amy Kenney; Nicholas Cox; M Aryana Bryan; Gerald Cochran
Journal:  Am J Health Syst Pharm       Date:  2021-02-08       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.